Quick Answer
Pulmonx Corp reported Cash And Cash Equivalents At Carrying Value of $69.75 million for the year ending 2025.
- Pulmonx Corp showed a decrease of -1.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Pulmonx Corp's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $15.73 million | Q1 2020: $16.24 million | Q2 2020: $43.35 million | Q3 2020: $39.81 million | Q1 2021: $209.28 million | Q2 2021: $198.70 million | Q3 2021: $188.08 million | Q1 2022: $129.17 million | Q2 2022: $121.95 million | Q3 2022: $112.40 million | Q1 2023: $110.41 million | Q2 2023: $101.58 million | Q3 2023: $94.95 million | Q1 2024: $70.16 million | Q2 2024: $63.46 million | Q3 2024: $63.31 million | Q1 2025: $74.56 million | Q2 2025: $75.47 million | Q3 2025: $76.55 million.
- Over the full 8 years of available data (2018 to 2025), Pulmonx Corp's Cash And Cash Equivalents At Carrying Value has grown by 1,591.3%.
- Historical annual values: Fiscal year 2025: $69.75 million | Fiscal year 2024: $70.91 million | Fiscal year 2023: $83.55 million | Fiscal year 2022: $101.74 million | Fiscal year 2021: $148.48 million | Fiscal year 2020: $231.56 million | Fiscal year 2019: $14.77 million | Fiscal year 2018: $4.12 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: